Sinovac Biotech (北京科兴生物制品有限公司) has taken action to apply its vaccine technology to the currently threatening strain of influenza, H1N1, commonly referred to as Swine flu. The company expects to receive a sample of the flu soon, which will enable Sinovac to begin manufacturing vaccine. Although Sinovac did not supply a time line for the process, a release quoted Weidong Yin, Sinovac’s Chairman, President and CEO, as saying, “Once this vaccine strain is available from the global health authorities, we will be ready to produce vaccine as needed." More details...

Stock Symbol: (NYSE Amex: SVA)